NIAID Acting Director Steps Down After Leadership Changes
Sen. Tammy Baldwin said Jeffery Taubenberger has stepped aside as acting director of the National Institute of Allergy and Infectious Diseases. The move follows earlier departures among senior NIAID officials since early 2025.
app.buzzsumo.comSen. Tammy Baldwin, a Democrat from Wisconsin, said at a hearing on 21 May that Jeffery Taubenberger has stepped aside as acting director of the National Institute of Allergy and Infectious Diseases. The NIAID could not be immediately reached for comment. The announcement comes after multiple senior officials at the institute have left their positions in the past year.
Three senior officials at the NIAID have been given the choice to either accept reassignment outside the institute or resign, according to sources at the NIAID. The institute has seen changes in nearly all of its senior leadership positions since early 2025.
Key Facts
Story Timeline
2 events- 21 May 2026
Sen. Tammy Baldwin said Jeffery Taubenberger stepped aside as NIAID acting director.
1 source@Nature - Early 2025 onward
Multiple senior NIAID officials left their positions.
1 source@Nature
Potential Impact
- 01
Further leadership vacancies may occur at the National Institute of Allergy and Infectious Diseases.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…